Publications en collaboration avec des chercheurs de Karolinska Institute (27)

2024

  1. Alzheimer's disease genetic pathways impact cerebrospinal fluid biomarkers and imaging endophenotypes in non-demented individuals

    Alzheimer's and Dementia

  2. Blood DNA methylomic signatures associated with CSF biomarkers of Alzheimer's disease in the EMIF-AD study

    Alzheimer's and Dementia

  3. Blood-based multivariate methylation risk score for cognitive impairment and dementia

    Alzheimer's and Dementia

  4. CSF proteomic profiles of neurodegeneration biomarkers in Alzheimer's disease

    Alzheimer's and Dementia

  5. GOIZ ZAINDU study: a FINGER-like multidomain lifestyle intervention feasibility randomized trial to prevent dementia in Southern Europe

    Alzheimer's Research and Therapy, Vol. 16, Núm. 1

  6. Involvement of the choroid plexus in Alzheimer’s disease pathophysiology: findings from mouse and human proteomic studies

    Fluids and Barriers of the CNS, Vol. 21, Núm. 1

2023

  1. Cerebrospinal fluid proteomic profiling of individuals with mild cognitive impairment and suspected non-Alzheimer's disease pathophysiology

    Alzheimer's and Dementia, Vol. 19, Núm. 3, pp. 807-820

  2. Whole-exome rare-variant analysis of Alzheimer's disease and related biomarker traits

    Alzheimer's and Dementia, Vol. 19, Núm. 6, pp. 2317-2331

2022

  1. Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer's disease

    Molecular neurodegeneration, Vol. 17, Núm. 1, pp. 27

  2. Correction: Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer’s disease (Molecular Neurodegeneration, (2022), 17, 1, (27), 10.1186/s13024-022-00521-3)

    Molecular Neurodegeneration

  3. Effects of age, amyloid, sex, and APOE ε4 on the CSF proteome in normal cognition

    Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, Vol. 14, Núm. 1

  4. Functional eigenvector centrality dynamics are related to amyloid deposition in preclinical Alzheimer’s Disease

    Alzheimer's and Dementia

  5. Genome-Wide Association Study of Alzheimer’s Disease Brain Imaging Biomarkers and Neuropsychological Phenotypes in the European Medical Information Framework for Alzheimer’s Disease Multimodal Biomarker Discovery Dataset

    Frontiers in Aging Neuroscience, Vol. 14

  6. Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum

    JAMA Neurology, Vol. 79, Núm. 3, pp. 228-243

  7. Rare variants in IFFO1, DTNB, NLRC3 and SLC22A10 associate with Alzheimer’s disease CSF profile of neuronal injury and inflammation

    Molecular Psychiatry, Vol. 27, Núm. 4, pp. 1990-1999

2021

  1. Csf proteomic alzheimer’s disease-predictive subtypes in cognitively intact amyloid negative individuals

    Proteomes, Vol. 9, Núm. 3

  2. TMEM106B and CPOX are genetic determinants of cerebrospinal fluid Alzheimer's disease biomarker levels

    Alzheimer's and Dementia, Vol. 17, Núm. 10, pp. 1628-1640

2020

  1. APOE ϵ4 genotype-dependent cerebrospinal fluid proteomic signatures in Alzheimer's disease

    Alzheimer's Research and Therapy, Vol. 12, Núm. 1

  2. Dickkopf-1 Overexpression in vitro Nominates Candidate Blood Biomarkers Relating to Alzheimer's Disease Pathology

    Journal of Alzheimer's Disease, Vol. 77, Núm. 3, pp. 1353-1368

  3. Pathophysiological subtypes of Alzheimer's disease based on cerebrospinal fluid proteomics

    Brain, Vol. 143, Núm. 12, pp. 3776-3792